Show simple item record

dc.contributor.authorPopat, Sen_US
dc.contributor.authorMellemgaard, Aen_US
dc.contributor.authorReck, Men_US
dc.contributor.authorHastedt, Cen_US
dc.contributor.authorGriebsch, Ien_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2017-04-03T10:37:11Z
dc.date.accessioned2018-02-19T16:28:49Z
dc.date.issued2017-06en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28326832en_US
dc.identifier.citationFuture Oncol, 2017, 13 (13), pp. 1159 - 1171en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1311
dc.identifier.eissn1744-8301en_US
dc.identifier.doi10.2217/fon-2016-0493en_US
dc.description.abstractPATIENTS & METHODS: We provide an update to a network meta-analysis evaluating the relative efficacy of nintedanib + docetaxel versus other second-line agents in adenocarcinoma histology non-small-cell lung cancer. RESULTS: Overall similarity of nintedanib + docetaxel versus ramucirumab + docetaxel, and versus nivolumab. Comparing nintedanib + docetaxel with nivolumab, hazards ratio (HR) of overall survival and progression-free survival (PFS) pointed in opposite directions (overall survival: HR: 1.20 [95% credible interval: 0.92-1.58]; PFS: HR: 0.91 [0.68-1.21]). Exploratory subgroup analysis indicated superiority of nivolumab in high PD-L1 expression level subgroups; results were more favorable for nintedanib in all subgroups with low (<1%, <5%, <10%) PD-L1 expression levels - in particular, with regard to PFS. CONCLUSION: Results demonstrated similar efficacy of nintedanib + docetaxel compared with the new therapeutic options ramucirumab + docetaxel and nivolumab, with potential differences in subgroups according to PD-L1 expression level.en_US
dc.format.extent1159 - 1171en_US
dc.languageengen_US
dc.language.isoengen_US
dc.relation.replaceshttps://repository.icr.ac.uk/handle/internal/553
dc.relation.replacesinternal/553
dc.subjectNSCLCen_US
dc.subjectchemotherapyen_US
dc.subjectimmunotherapyen_US
dc.subjectnintedaniben_US
dc.subjectnivolumaben_US
dc.subjectsecond-line treatmenten_US
dc.subjectAdenocarcinomaen_US
dc.subjectAntibodies, Monoclonalen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectB7-H1 Antigenen_US
dc.subjectCarcinoma, Non-Small-Cell Lungen_US
dc.subjectDisease-Free Survivalen_US
dc.subjectDocetaxelen_US
dc.subjectGene Expression Regulation, Neoplasticen_US
dc.subjectHumansen_US
dc.subjectIndolesen_US
dc.subjectNetwork Meta-Analysisen_US
dc.subjectNivolumaben_US
dc.subjectTaxoidsen_US
dc.subjectTreatment Outcomeen_US
dc.titleNintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.2217/fon-2016-0493en_US
rioxxterms.licenseref.startdate2017-06en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfFuture Oncolen_US
pubs.issue13en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume13en_US
pubs.embargo.termsNot knownen_US
icr.researchteamThoracic Oncologyen_US
dc.contributor.icrauthorPopat, Sanjayen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record